Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 18;65(11):e0228820.
doi: 10.1128/AAC.02288-20. Epub 2021 Aug 9.

Imipenem-Relebactam Susceptibility and Genotypic Characteristics of Carbapenem-Resistant Enterobacterales Identified during Population-Based Surveillance

Sam Horwich-Scholefield  1 , Tyler Lloyd  2 , Vici Varghese  2 , Emily Yette  1 , Sandra Huang  1 , Mark Pandori  3
Affiliations

Imipenem-Relebactam Susceptibility and Genotypic Characteristics of Carbapenem-Resistant Enterobacterales Identified during Population-Based Surveillance

Sam Horwich-Scholefield et al. Antimicrob Agents Chemother. .

Abstract

Laboratories submit all carbapenem-resistant Enterobacter, Escherichia coli, and Klebsiella species to the Alameda County Public Health Department (ACPHD). ACPHD evaluated 75 isolates submitted during 9 months for susceptibility to imipenem-relebactam (I-R) and, using whole-genome sequencing, identified β-lactamase genes. Of 60 (80%) isolates susceptible to I-R, 8 (13%) had detectable carbapenemase genes, including 4 KPC, two NDM, and two OXA-48-like; we described the relationship between the presence of β-lactamase resistance genes and susceptibility to I-R.

Keywords: NDM; carbapenem resistance; imipenem-relebactam; whole-genome sequencing; β-lactamase inhibitor.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Carbapenemase and ESBL genes by imipenem-relebactam MIC (n = 75). Of 14 (19%) isolates that were resistant to I-R, 5 had detectable genes for NDM-5, 4 had NDM-1, 2 had NDM-7, and 1 was positive for both NDM-5 and OXA-18 genes. Two resistant isolates did not have detectable carbapenemase genes.
See this image and copyright information in PMC

References

    1. U.S. Centers for Disease Control and Prevention. 2019. Antibiotic resistance threats in the United States. U.S. Department of Health and Human Services. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-re....
    1. Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, Pandey R, Doi Y, Kreiswirth BN, Nguyen MH, Clancy CJ. 2017. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 61:e02097-16. 10.1128/AAC.02097-16. - DOI - PMC - PubMed
    1. Sun D, Rubio-Aparicio D, Nelson K, Dudley MN, Lomovskaya O. 2017. Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 61:e01694-17. 10.1128/AAC.01694-17. - DOI - PMC - PubMed
    1. Dulyayangkul P, Douglas EJA, Lastovka F, Avison MB. 2020. Resistance to ceftazidime/avibactam plus meropenem/vaborbactam when both are used together is achieved in four steps in metallo-β-lactamase-negative Klebsiella pneumoniae. Antimicrob Agents Chemother 64:e00409-20. 10.1128/AAC.00409-20. - DOI - PMC - PubMed
    1. Motsch J, Murta de Oliveira C, Stus V, Köksal I, Lyulko O, Boucher HW, Kaye KS, File TM, Brown ML, Khan I, Du J, Joeng H-K, Tipping RW, Aggrey A, Young K, Kartsonis NA, Butterton JR, Paschke A. 2020. RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin Infect Dis 70:1799–1808. 10.1093/cid/ciz530. - DOI - PMC - PubMed

Publication types

MeSH terms